Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 187.72 Billion KRW | -2.31% |
| 2022 | 192.17 Billion KRW | 196.59% |
| 2021 | 64.79 Billion KRW | -60.96% |
| 2020 | 165.96 Billion KRW | 76.11% |
| 2019 | 94.24 Billion KRW | 20.06% |
| 2018 | 78.49 Billion KRW | 57.27% |
| 2017 | 49.91 Billion KRW | 6101.72% |
| 2016 | -831.61 Million KRW | -102.36% |
| 2015 | 35.2 Billion KRW | 14.21% |
| 2014 | 30.82 Billion KRW | 44.44% |
| 2013 | 21.33 Billion KRW | -48.86% |
| 2012 | 41.72 Billion KRW | -19.51% |
| 2011 | 51.84 Billion KRW | 134.97% |
| 2010 | 22.06 Billion KRW | 213.65% |
| 2009 | 7.03 Billion KRW | 435.77% |
| 2008 | -2.09 Billion KRW | -1665.51% |
| 2007 | 133.82 Million KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 179.28 Billion KRW | 2.42% |
| 2024 Q1 | 175.03 Billion KRW | -6.76% |
| 2023 Q3 | 190.01 Billion KRW | -0.96% |
| 2023 Q2 | 191.84 Billion KRW | -25.95% |
| 2023 FY | 187.72 Billion KRW | -2.31% |
| 2023 Q1 | 259.09 Billion KRW | 34.82% |
| 2023 Q4 | 187.72 Billion KRW | -1.2% |
| 2022 Q2 | 206.69 Billion KRW | 136.2% |
| 2022 FY | 192.17 Billion KRW | 196.59% |
| 2022 Q4 | 192.17 Billion KRW | 11.9% |
| 2022 Q3 | 171.73 Billion KRW | -16.92% |
| 2022 Q1 | 87.5 Billion KRW | 35.05% |
| 2021 Q2 | 145.82 Billion KRW | -0.81% |
| 2021 Q3 | 24.89 Billion KRW | -82.93% |
| 2021 Q4 | 64.79 Billion KRW | 160.25% |
| 2021 FY | 64.79 Billion KRW | -60.96% |
| 2021 Q1 | 147.01 Billion KRW | -11.42% |
| 2020 Q3 | 84.48 Billion KRW | -16.22% |
| 2020 FY | 165.96 Billion KRW | 76.11% |
| 2020 Q4 | 165.96 Billion KRW | 96.45% |
| 2020 Q1 | 90.18 Billion KRW | -4.3% |
| 2020 Q2 | 100.83 Billion KRW | 11.81% |
| 2019 FY | 94.24 Billion KRW | 20.06% |
| 2019 Q4 | 94.24 Billion KRW | 4.94% |
| 2019 Q3 | 89.8 Billion KRW | -8.0% |
| 2019 Q2 | 97.61 Billion KRW | -2.96% |
| 2019 Q1 | 100.59 Billion KRW | 28.15% |
| 2018 Q4 | 78.49 Billion KRW | 23.04% |
| 2018 Q2 | 49.14 Billion KRW | 15.4% |
| 2018 FY | 78.49 Billion KRW | 57.27% |
| 2018 Q1 | 42.58 Billion KRW | -14.67% |
| 2018 Q3 | 63.79 Billion KRW | 29.8% |
| 2017 Q1 | 1.58 Billion KRW | 290.69% |
| 2017 Q2 | 37.92 Billion KRW | 2291.29% |
| 2017 Q4 | 49.91 Billion KRW | 32.31% |
| 2017 Q3 | 37.72 Billion KRW | -0.52% |
| 2017 FY | 49.91 Billion KRW | 6101.72% |
| 2016 Q4 | -831.61 Million KRW | 0.0% |
| 2016 FY | -831.61 Million KRW | -102.36% |
| 2015 Q2 | 24.62 Billion KRW | -13.31% |
| 2015 FY | 35.2 Billion KRW | 14.21% |
| 2015 Q4 | 35.2 Billion KRW | 21.02% |
| 2015 Q3 | 29.08 Billion KRW | 18.09% |
| 2015 Q1 | 28.41 Billion KRW | -7.82% |
| 2014 Q3 | 18.31 Billion KRW | 3.36% |
| 2014 Q4 | 30.82 Billion KRW | 68.27% |
| 2014 FY | 30.82 Billion KRW | 44.44% |
| 2014 Q1 | 16.75 Billion KRW | -21.5% |
| 2014 Q2 | 17.72 Billion KRW | 5.79% |
| 2013 Q3 | 23.66 Billion KRW | 1.13% |
| 2013 Q4 | 21.33 Billion KRW | -9.83% |
| 2013 FY | 21.33 Billion KRW | -48.86% |
| 2013 Q1 | 39.1 Billion KRW | -6.28% |
| 2013 Q2 | 23.4 Billion KRW | -40.17% |
| 2012 Q2 | 39.72 Billion KRW | -5.78% |
| 2012 Q1 | 42.16 Billion KRW | -18.67% |
| 2012 FY | 41.72 Billion KRW | -19.51% |
| 2012 Q4 | 41.72 Billion KRW | -6.26% |
| 2012 Q3 | 44.51 Billion KRW | 12.06% |
| 2011 Q3 | 47.1 Billion KRW | 5.35% |
| 2011 FY | 51.84 Billion KRW | 134.97% |
| 2011 Q1 | 40.94 Billion KRW | 85.58% |
| 2011 Q4 | 51.84 Billion KRW | 10.07% |
| 2011 Q2 | 44.7 Billion KRW | 9.19% |
| 2010 Q1 | 19.7 Billion KRW | 180.19% |
| 2010 FY | 22.06 Billion KRW | 213.65% |
| 2010 Q4 | 22.06 Billion KRW | 10.91% |
| 2010 Q3 | 19.89 Billion KRW | -3.27% |
| 2010 Q2 | 20.56 Billion KRW | 4.34% |
| 2009 Q1 | 7.7 Billion KRW | 467.78% |
| 2009 FY | 7.03 Billion KRW | 435.77% |
| 2009 Q4 | 7.03 Billion KRW | 21.24% |
| 2009 Q3 | 5.8 Billion KRW | 56.04% |
| 2009 Q2 | 3.71 Billion KRW | -51.74% |
| 2008 Q2 | -2.06 Billion KRW | -160.72% |
| 2008 Q4 | -2.09 Billion KRW | -213.16% |
| 2008 Q3 | 1.85 Billion KRW | 189.78% |
| 2008 FY | -2.09 Billion KRW | -1665.51% |
| 2008 Q1 | 3.39 Billion KRW | 2437.7% |
| 2007 FY | 133.82 Million KRW | 0.0% |
| 2007 Q1 | 13.17 Billion KRW | 0.0% |
| 2007 Q3 | 3.7 Billion KRW | -38.13% |
| 2007 Q4 | 133.82 Million KRW | -96.39% |
| 2007 Q2 | 5.98 Billion KRW | -54.58% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -2032.726% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 67.182% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 39.613% |
| HANDOK Inc. | 283.45 Billion KRW | 33.772% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -835.264% |
| Yuhan Corporation | -69.18 Billion KRW | 371.336% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 3.208% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 5193.255% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 63.751% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 678.837% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -148.072% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -409.613% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -127.493% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -647.67% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -2032.726% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 217.442% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 6.578% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | -9.819% |
| JW Holdings Corporation | 480.68 Billion KRW | 60.946% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -14.063% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -159625.716% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -21.608% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -7883.943% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -716.157% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | -7.29% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -261.192% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -2032.726% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -18.592% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 47.588% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -21.608% |
| Yuhan Corporation | -69.18 Billion KRW | 371.336% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -38.044% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -214.588% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 56.256% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -21.608% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -61.505% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -1042.933% |
| CKD Bio Corp. | 143.29 Billion KRW | -31.007% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -61.741% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 880.194% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 519.653% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -7883.943% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 55.603% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 361.313% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -148.072% |
| JW Lifescience Corporation | 26.09 Billion KRW | -619.521% |